Bulk Manufacturer of Controlled Substances Application: SpecGx LLC
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
SpecGx LLC, a pharmaceutical manufacturer, has filed an application with the U.S. Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of one or more basic classes of controlled substances under the Controlled Substances Act (CSA). This notice is published in the Federal Register to allow interested parties — including competitors, public health advocates, and law enforcement agencies — to submit comments or request a hearing regarding the application within the statutory comment period. Bulk manufacturers of controlled substances must obtain DEA registration and demonstrate that their operations are consistent with the public interest, including adequate security measures, recordkeeping, and prevention of diversion into illicit channels. Approval of this application would authorize SpecGx LLC to legally produce schedule I–V controlled substances in bulk quantities, typically for supply to other DEA-registered entities such as pharmaceutical formulators, researchers, or distributors.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- SpecGx LLC has applied for DEA registration as a bulk manufacturer of controlled substances under the Controlled Substances Act
- Application covers one or more basic classes of scheduled controlled substances (schedules I–V)
- Federal Register notice opens a public comment and hearing request period for interested parties
+ 3 more changes with Pro
Obligations
What this law requires
Demonstrate that manufacturing operations are consistent with the public interest as part of DEA registration application
Obtain DEA registration as a bulk manufacturer of controlled substances before legally producing schedule I–V controlled substances
Implement adequate security measures to prevent diversion of controlled substances into illicit channels
Maintain comprehensive recordkeeping systems for all controlled substance manufacturing operations
Allow interested parties, including competitors, public health advocates, and law enforcement agencies, to submit comments or request a hearing within the statutory comment period